Compare
AbbVie vs BioMarin Pharmaceutical (ABBV vs BMRN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and BioMarin Pharmaceutical (BMRN) +6.1%; so far this year the figures are +27.5% and -5.7%.
AbbVie is the larger company by market value, about 47.5 times the size of BioMarin Pharmaceutical.
Revenue grew +10.7% at ABBV and +18.1% at BMRN over the last year.
ABBV yields 2.38%. BMRN pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | BMRN | |
|---|---|---|
| Price | $291.31 | $56.03 |
| 1-day | +1.07% | -0.16% |
| YTD | +27.49% | -5.72% |
| 1 year | +34.39% | +6.12% |
| 3 years | +104.47% | -33.31% |
| Market cap | $514.9B | $10.8B |
| P/E | 50.1 | — |
| P/S | 7.80 | 2.97 |
| P/B | — | 1.73 |
| Revenue growth | +10.70% | +18.10% |
| EPS growth | +340.20% | -103.70% |
| Gross margin % | 73.7 | 76.0 |
| Net margin % | 15.7 | -0.5 |
| ROE % | — | -0.3 |
| Debt / equity | — | 0.67 |
| FCF yield % | 3.7 | 5.1 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.34 |
| RSI (14) | 59.7 | 45.2 |
| Technical rating |